Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

PURPOSE: Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Blakeley, Jaishri O., Ye, Xiaobu, Duda, Dan G., Halpin, Chris F., Bergner, Amanda L., Muzikansky, Alona, Merker, Vanessa L., Gerstner, Elizabeth R., Fayad, Laura M., Ahlawat, Shivani, Jacobs, Michael A., Jain, Rakesh K., Zalewski, Christopher, Dombi, Eva, Widemann, Brigitte C., Plotkin, Scott R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872317/
https://ncbi.nlm.nih.gov/pubmed/26976425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.3817
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados